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Abstract
We studied the association between chlorhexidine gluconate (CHG) concentration on skin and 
resistant bacterial bioburden. CHG was almost always detected on the skin, and detection of 
methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, and 
vancomycin-resistant Enterococcus on skin sites was infrequent. However, we found no 
correlation between CHG concentration and bacterial bioburden.
Chlorhexidine gluconate (CHG) bathing is a widely implemented infection control measure.
1
 In randomized trials and quasi-experimental studies, CHG has been demonstrated to 
decrease patient infection rates, frequency of healthcare worker contamination, and 
transmission of antibiotic-resistant bacteria.2–4 CHG is believed to act by reducing 
contamination of the skin and, subsequently, the surrounding environment.5 One study 
showed an inverse association between CHG concentration and gram-positive bacterial 
burden when CHG concentrations were >18.75 μg/mL6; however, this was a single-center 
study with only 20 patients. Despite increasing evidence suggesting the benefits of CHG 
bathing,2–4 little research has been done to guide optimal CHG bathing practices by 
determining whether the CHG concentrations are associated with decreases in resistant 
bacterial bioburden in real-world settings.
The aim of our study was to examine the association between CHG concentrations and 
methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant 
Enterobacteriaceae (CRE), and vancomycin-resistant Enterococcus (VRE) bioburden on the 
skin. We hypothesized that the bioburden decreases as the CHG concentration on the skin 
increases. Additionally, we explored whether bacterial bioburden is affected by method and 
the time since the last CHG bath.
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Methods
From May 2017 to August 2018, patients with MRSA, CRE, and VRE from 4 hospitals in 
the United States were enrolled as a part of a multicenter cohort study. All participants had a 
clinical or surveillance culture positive for 1 of these organisms within the previous 7 days. 
Intact skin was cultured to quantify bacterial bioburden using a sterile stencil at 2 sites: the 
antecubital fossa and the chest. CHG samples were collected from an adjacent area used to 
sample bacterial bioburden. At the time of patient enrollment, we recorded the method of 
CHG bathing (ie, 2% impregnated cloth or 4% CHG liquid soap) and time since the last 
CHG bath. To quantify bioburden, swabs were inoculated onto selective plates to count the 
colony-forming units per milliliter (CFU/mL) after serial dilution. A colorimetric, 
semiquantitative method was used to estimate CHG concentrations as previously described.
6–8
Statistical analysis
Descriptive statistics for bioburden and CHG concentration were calculated. The CHG 
concentration was analyzed both as a continuous and a dichotomous variable (≤20 ppm vs 
>20 ppm) based on prior studies where a CHG concentration ≤18.75 μg/mL was considered 
inadequate to lower gram-positive bacteria.6,8 The bacterial bioburden (x + 1) was log 
transformed, expressed in log10 CFU/mL, and analyzed as a continuous variable. All 
samples of MRSA, CRE, and VRE were analyzed in individual groups to study the 
relationships among the bacterial burden, CHG concentrations, time since last bath, and type 
of bath. The χ2 test, Spearman’s correlation, and linear regression were computed. Results 
were summarized as mean estimates and corresponding 95% confidence intervals.
Results
In total, 253 patients were enrolled in the study: 89 with MRSA (35%), 108 with CRE 
(42%), and 56 with VRE (22%). Moreover, 50 MRSA patients (56%) and 26 CRE patients 
(25%) were bathed with CHG cloths. All VRE patients were bathed with CHG liquid soap. 
The medians and interquartile ranges (IQRs) for CHG concentrations were as follows: 
MRSA,100 ppm (IQR, 30–200); CRE, 20 ppm (IQR, 0–100); and VRE, 10 ppm (IQR, 5–
50). The median bacterial bioburdens were zero for MRSA, CRE, and VRE.
On the arm skin site, we detected MRSA in 17 patients (19%), CRE in 16 patients (15%), 
and VRE in 12 patients (21%). Detectable CHG levels were observed in 82 MRSA patients 
(93%), 81 CRE patients (79%), and 44 VRE patients (79%). We found a nonsignificant 
negative correlation between bioburden and CHG concentration for MRSA (rs = −0.11; P = .
28) and CRE (rs = −0.02; P = .82), and a nonsignificant positive correlation was observed for 
VRE (rs = 0.15; P = .28).
On the chest skin site, MRSA was detected in 25 patients (28%), CRE was detected in 18 
patients (17%), and VRE was detected in 7 patients (13%). Detectable CHG levels were 
observed in 83 MRSA patients (95%), 78 CRE patients (72%), and 43 VRE patients (77%). 
We found a nonsignificant negative correlation between bioburden and CHG concentration 
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for MRSA (rs = −0.16; P = .12) and nonsignificant positive correlations for CRE (rs = 0.18; 
P = .06) and VRE (rs = 0.24; P = .06).
We found no significant difference in bacterial bioburden when comparing CHG 
concentrations of >20 ppm with CHG concentrations ≤20 ppm (Table 1). On the arm skin 
site, we detected MRSA in 13 patients (18%), CRE in 6 patients (11%), and VRE in 6 
patients (30%) with CHG concentrations >20 ppm, compared to MRSA in 4 patients (22%), 
CRE in 10 patients (19%), and VRE in 6 patients (17%) with CHG concentrations ≤20 ppm. 
On the chest skin site, we detected MRSA in 16 patients (24%), CRE in 10 patients (19%), 
and VRE in 5 patients (23%) among those with CHG concentrations >20 ppm, compared to 
MRSA in 9 patients (43%), CRE in 8 patients (14%), and VRE in 2 patients (6%) with CHG 
concentrations ≤20 ppm. The bioburden did not differ by the method of CHG bath. The 
mean estimates of bioburden on both skin sites did not show a significant decrease with an 
increase in CHG concentration from ≤20 ppm to >20 ppm and were not affected by the time 
since the last CHG bath (Table 2).
Discussion
In our study, CHG concentrations on the skin were high and the detection of MRSA, VRE, 
and CRE on 2 skin sites was infrequent. We did not find the hypothesized association 
between higher CHG levels and lower bacterial burden. Furthermore, our study suggests that 
CHG bathing reduces bacterial bioburden irrespective of the application method used.9
We did not find an inverse association between bacterial burden and CHG concentration 
when CHG concentration analyzed as a continuous variable6,8 nor as a categorical variable 
≤20 ppm or >20 ppm. Thus, CHG bathing may have a beneficial impact even at lower 
detectable concentrations. Our results are supported by Edmiston et al,10 who found that the 
minimum inhibitory concentration of CHG for Staphylococcus skin isolates was 4.8 ppm, 
which is approximately the lower limit (5 ppm) of CHG detection in our assay. We used the 
same method to measure CHG levels as in previous studies6–8; however, the incongruent 
associations observed between the skin bioburden and CHG concentration, time since the 
last CHG bath, and CHG concentration raise the concern that the CHG assay for detection of 
CHG levels may not be reliable or that another CHG level monitoring device may be needed 
to acquire more accurate quantitative levels. Our findings are inconsistent with those 
presented by Popovich et al6; however, we studied different bacteria, and our sample size 
was notably larger.
A limitation of our study was that we quantified bioburden and recorded CHG 
concentrations only at 2 skin sites in comparison to previous studies that included 3–5 skin 
sites.6–8 Moreover, with the high number of skin sites with no bacteria detected, our study 
was likely underpowered to assess the association between CHG concentration and bacterial 
bioburden.
In summary, our findings suggest that in hospitalized patients bathed with CHG, bacterial 
MRSA, CRE, and VRE bioburden on the skin is low, irrespective of CHG bathing method 
and the time since the last CHG bath. However, considering the inconsistent association 
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between levels of CHG on the skin and bacterial bioburden, additional research is needed. 
The daily frequency of CHG bathing has been arbitrarily chosen and standardized across all 
populations. It is plausible that CHG bathing frequency could be optimized for individual 
patient populations to augment the reduction of bacteria while minimizing side effects. To 
better implement these varying CHG bathing approaches, greater understanding of the 
association between CHG concentrations and resistant-bacterial bioburden is needed.
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